EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …
Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.
For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer.
However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound.
Extracellular vesicles (EVs) are small, membrane-bound particles continuously released by living cells throughout their lifespan. The cargo of EVs are not exported randomly; they reflect the health status of their parental cells and are enriched with bioactive components involved in critical cellular functions. EVs serve as convenient 'windows' into cellular processes, generally transmitting specific intercellular messages regionally and across organs.
When a blood sample is taken, it contains billions of these EVs including hundreds of thousands derived from specific organs like the liver. For more visual explanations, please watch our 3D video.
Mursla Bio's
This dynamic biopsy is made possible by leveraging extracellular vesicle (EV) science and an innovative approach called extracellular omics, alongside Mursla Bio’s pioneering technologies. These technologies include: (i) Organ-specific EV isolation, (ii) AI-enabled multi-omics biomarker discovery workflow, and (iii) scalable EV multi-omics assays for clinical use.
EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with …
Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics …
